Point of View: Electrophysiological Endpoints Differ When Comparing the Mode of Action of Highly Successful Anti-arrhythmic Drugs in the CAVB Dog Model With TdP

J Cardiovasc Pharmacol. 2019 Dec;74(6):499-507. doi: 10.1097/FJC.0000000000000748.

Abstract

In the anaesthetized, chronic atrioventricular block (CAVB) dog, ventricular ectopic beats and Torsade de pointes arrhythmias (TdP) are believed to ensue from an abrupt prolongation of ventricular repolarization and increased temporal dispersion of repolarization, quantified as short-term variability (STV). These TdP stop spontaneously or, when supported by substantial spatial dispersion of repolarization (SDR), degenerate into ventricular fibrillation. However, most studies involving ventricular arrhythmias do not quantify SDR by means of an electrophysiological parameter. Therefore, we reviewed the effects of 4 highly effective anti-arrhythmic drugs (flunarizine, verapamil, SEA-0400, and GS-458967) on the repolarization duration and associated STV. All drugs were tested as anti-arrhythmic strategies against TdP in CAVB dogs, their high anti-arrhythmic efficacy was defined as suppressing drug-induced TdP in 100% of the experiments. This comparison demonstrates that even though the anti-arrhythmic outcome was similar for all drugs, distinct responses of repolarization duration and associated STV were observed. Moreover, the aforementioned and commonly adopted electrophysiological parameters were not always sufficient in predicting TdP susceptibility, and additional quantification of the SDR proved to be of added value in these studies. The variability in electrophysiological responses to the different anti-arrhythmic drugs and their inconsistent adequacy in reflecting TdP susceptibility, can be explained by distinct modes of interference with TdP development. As such, this overview establishes the separate involvement of temporal and spatial dispersion in ventricular arrhythmogenesis in the CAVB dog model and proposes SDR as an additional parameter to be included in future fundamental and/or pharmaceutical studies regarding TdP arrhythmogenesis.

Publication types

  • Review

MeSH terms

  • Action Potentials / drug effects*
  • Aniline Compounds / pharmacology
  • Animals
  • Anti-Arrhythmia Agents / pharmacology*
  • Atrioventricular Block / diagnosis
  • Atrioventricular Block / drug therapy*
  • Atrioventricular Block / physiopathology
  • Chronic Disease
  • Disease Models, Animal
  • Dogs
  • Electrophysiologic Techniques, Cardiac
  • Endpoint Determination
  • Flunarizine / pharmacology
  • Heart Rate / drug effects*
  • Phenyl Ethers / pharmacology
  • Pyridines / pharmacology
  • Time Factors
  • Torsades de Pointes / diagnosis
  • Torsades de Pointes / drug therapy*
  • Torsades de Pointes / physiopathology
  • Triazoles / pharmacology
  • Verapamil / pharmacology

Substances

  • 6-(4-(trifluoromethoxy)phenyl)-3-(trifluoromethyl)(1,2,4)triazolo(4,3-a)pyridine
  • Aniline Compounds
  • Anti-Arrhythmia Agents
  • Phenyl Ethers
  • Pyridines
  • SEA 0400
  • Triazoles
  • Verapamil
  • Flunarizine